Welcome to our dedicated page for Varonis Sys SEC filings (Ticker: VRNS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking how Varonis Systems monetises its patented data-security platform can feel like decoding its own anomaly-detection engine. Subscription conversions, annual recurring revenue and insider option exercises hide deep inside the company’s 10-K, 10-Q and Form 4 stream—exactly where most investors get lost.
Stock Titan surfaces the signal. Our AI reads every Varonis Systems quarterly earnings report 10-Q filing, flags changes in ARR or cloud-migration costs, and delivers plain-English answers for anyone understanding Varonis Systems SEC documents with AI. Need real-time alerts? We post Varonis Systems Form 4 insider transactions real-time so you can monitor Varonis Systems executive stock transactions Form 4 minutes after they hit EDGAR.
Looking for a single place to review every disclosure type? You’ll find:
- Varonis Systems annual report 10-K simplified with AI-driven highlights of R&D spend and cybersecurity risk factors.
- Varonis Systems proxy statement executive compensation decoded to show how performance stock units align with ARR goals.
- Varonis Systems 8-K material events explained, from acquisitions of cloud-security startups to leadership changes.
- Continuous log of Varonis Systems insider trading Form 4 transactions paired with market-moving 8-K notices.
Whether you’re seeking a quick Varonis Systems earnings report filing analysis or want Varonis Systems SEC filings explained simply, Stock Titan delivers AI-powered summaries, redline comparisons and key-metric dashboards—all updated the moment EDGAR releases them. Spend less time hunting through hundreds of pages and more time deciding if Varonis’ next move in zero-trust data security fits your portfolio.
Varonis Systems (VRNS) filed its Q3 2025 10‑Q. Revenue rose to $161.6M from $148.1M a year ago as SaaS grew to $125.8M while term licenses declined to $24.8M. Gross profit was $126.4M versus $124.1M. Operating expenses increased, leading to a larger operating loss of $35.9M and a net loss of $29.9M (vs. $18.3M).
The shift to subscriptions continued: deferred revenues reached $341.5M (current and long‑term combined), and remaining performance obligations were $930.7M, with about 54% expected over the next 12 months. Cash from operating activities for the first nine months was $122.7M.
Liquidity remained solid with cash and cash equivalents of $157.4M, current marketable securities of $513.9M, and long‑term marketable securities of $395.7M. The company settled its 2025 converts and had $451.8M net carrying amount of 2029 notes outstanding. It completed a $100M buyback earlier in 2025 and authorized a new $150M program in October 2025. Acquisitions of Cyral and SlashNext added technology and customers, increasing goodwill to $135.2M. Shares outstanding were 117,897,308 as of October 24, 2025.
Varonis Systems (VRNS) furnished an 8-K announcing financial results for the third quarter ended September 30, 2025, via a press release attached as Exhibit 99.1. The company notes the information is furnished and not filed under the Exchange Act, and it is incorporated by reference only if expressly stated in a future filing.
Guy Melamed, identified as CFO and COO of Varonis Systems, Inc. (VRNS), reported two sales of common stock under a Rule 10b5-1 trading plan. On 08/28/2025 he sold 3,892 shares at a weighted average price of $59.52, leaving him with 413,605 shares. On 08/29/2025 he sold 1,500 shares at a weighted average price of $59.59, leaving 412,105 shares beneficially owned.
The filing states the trades were executed pursuant to a 10b5-1 plan adopted in 2024 and discloses weighted average price ranges for the transactions. The form is signed by an attorney-in-fact on behalf of the reporting person.
Guy Melamed, Chief Financial Officer and Chief Operating Officer of Varonis Systems, Inc. (VRNS), reported the sale of 10,400 shares of Varonis common stock on 08/22/2025. The shares were sold under a Rule 10b5-1 trading plan adopted in 2024 at a weighted-average price of $59.53 per share, with transaction prices ranging from $59.50 to $59.57. After the sale, Melamed beneficially owned 417,497 shares. The Form 4 was submitted and signed by an attorney-in-fact on 08/26/2025. The filer notes willingness to provide detailed per-price sale data upon request.
Varonis Systems, Inc. (VRNS) notice reports a proposed sale of 100,000 shares of common stock through Morgan Stanley Smith Barney LLC on NASDAQ, with an aggregate market value of $5,852,000 and 112,047,109 shares outstanding. The securities were acquired as restricted stock units on 02/29/2024 and payment/settlement is recorded as N/A. The filer reports no sales in the past three months and includes a representation about absence of undisclosed material adverse information.
Notice of Proposed Sale under Rule 144: This Form 144 reports a proposed sale of 56,940 common shares of Varonis Systems, Inc. (VRNS) with an aggregate market value of $3,332,128.80, using Morgan Stanley Smith Barney LLC as broker and an approximate sale date of 08/22/2025. The shares were acquired as Performance Stock Units on 02/29/2024. The filing shows 112,047,109 shares outstanding. The record also lists two 10b5-1 sales by Guy Melamed within the past three months: 42,705 shares sold on 08/13/2025 for $2,465,133.31 and 51,889 shares sold on 08/01/2025 for $2,859,281.08. The filer attests to Rule 10b5-1 representations and confirms no undisclosed material adverse information.
Insider sale by Varonis CFO/COO under 10b5-1 plan. Guy Melamed, who serves as Chief Financial Officer and Chief Operating Officer, reported a sale of 42,705 shares of Varonis Systems, Inc. (VRNS) on 08/13/2025 at a weighted average price of $57.72 per share. The filing states the sale was made pursuant to a Rule 10b5-1 trading plan adopted in 2024. After this transaction, Melamed beneficially owned 427,897 shares. The Form 4 was signed by an attorney-in-fact on behalf of Melamed and was filed as an individual report.
Varonis Systems filed a Form 144 notifying a proposed sale of 42,705 common shares through Morgan Stanley Smith Barney, with an aggregate market value of $2,427,352.20. The filing lists 112,047,109 shares outstanding and an approximate sale date of 08/13/2025.
The securities were acquired as Restricted Stock Units on 02/29/2024. The notice also records a prior 10b5-1 sale for Guy Melamed of 51,889 shares on 08/01/2025 with gross proceeds of $2,859,281.08. The filing includes the standard seller representation regarding undisclosed material information and references Rule 10b5-1 plan considerations.
Varonis Systems (VRNS) Form 4 – Insider Transaction
Chief Financial & Operating Officer Guy Melamed sold 51,889 common shares on 08/01/2025 under a pre-arranged Rule 10b5-1 plan. The shares were disposed at a weighted-average price of $55.10 (range $55.01–$55.24), generating proceeds of roughly $2.9 million. Following the sale, Melamed’s direct ownership stands at 470,602 shares.
No derivative securities were involved and no acquisitions were reported. The filing signals a reduction of approximately 10% of Melamed’s prior direct stake, yet he retains a sizeable position. Because the transaction was executed through a 10b5-1 program, it was scheduled in advance and may not reflect current views on VRNS valuation.
FAQ
What is the current stock price of Varonis Sys (VRNS)?
What is the market cap of Varonis Sys (VRNS)?
